Controlling Cell Fate In Vivo
Weian Zhao,J. Karp
DOI: https://doi.org/10.1002/cbic.200900445
IF: 3.2
2009-09-21
ChemBioChem
Abstract:Consider the injection of a small biomaterial device under the skin that could trigger the immune system to attack cancer, treat inflammatory disease, or slow the progression of age-related tissue degeneration. The most recent advances at the interface of chemistry, material science, cell biology, and medicine suggest that this concept is becoming a reality—the key relies on the design of appropriate functional materials to control cell trafficking and cell fate directly in the patient’s body. Biomaterials, with well-defined chemical, biological, physical, and structural property/function relationships, have been explored as the basis for tissue engineering, cell therapy, and regenerative medicine. Traditionally, biodegradable polymers are used as scaffolds on which cells are seeded and sometimes matured (that is, proliferated and differentiated) in vitro; this is followed by implantation to replace diseased and damaged tissues or organs. The use of biomaterials as cell carriers has certain advantages compared to the direct injection of cells for cell therapy. 6] In the case of direct cell infusion or injection (which represents the most commonly utilized cell delivery strategy in the clinic—that is, bone marrow transplantation), the cell delivery process often leads to: 1) massive cell death of the transplanted cells due to mass transport limitations of oxygen and nutrients (in the case of local injection), 2) extremely poor (typically <3 %) homing/engraftment efficiency to a the target tissue (in the case of systemically infused cells), and 3) the loss of control over the fate of the transplanted cells. By contrast, the use of biomaterials as cell carriers provides a substrate that can be used to promote cell survival and can provide the necessary physical constraints to better localize cells. The biomaterial can also serve as a template for guiding the formation of new tissue and for promoting engraftment with the host. In particular, the third generation “bioactive” materials integrated with drugs, proteins, peptides, genetic materials, and other biomolecules can provide control over transplanted cells with respect to cell adhesion, proliferation, migration, differentiation, and production of paracrine factors or extracellular matrix. However, such in vitro procedures require the isolation of primary cells and ex vivo cell manipulation; this results in potential activation of cells or modification of their phenotype, imACHTUNGTRENNUNGmune rejection following implantation, high cost, and other scale-up issues and substantial regulatory issues. 6] Moreover, ex vivo cell manipulation, which depends largely on culture conditions, might lead to the loss of cell therapeutic capabilities and variations between trials. In a potentially ideal scenario (Figure 1), one might dream of a biomaterial that, once implanted into a patient, can recruit native cells, program them (using the cues that are loaded on or within the materials) and then send the cells throughout the body to treat injuries or diseased tissues. The most recent advances from Mooney and his colleagues at Harvard University showed this dream is well on its way to becoming a reality. The new generation of biomaterials, when properly integrated with cell adhesion molecules, growth factors and genetic material, can now provide exquisite control over the in vivo fate of host cells—without ex vivo manipulation—and this could lead to more effective regenerative therapeutics. Mooney and co-workers first asked how cells could be recruited in vivo by using a biomaterials approach. 9] The